NON-ALCOHOLIC FATTY LIVER FOR PRIMARY CARE PHYSICIANS

Ma Ai Thanda Han, MD, FACP

- Assistant Professor/Transplant Hepatologist & Gastroenterologist
- Division of Gastroenterology and Hepatology
- **Banner University Medical Center**
- University of Arizona

Disclosure

Nothing to disclose

Outline

- Background
- How to stratify risk
 - Which patient need to be referred to the Hepatology Clinic
- Management
 - Life-Style Intervention
 - Current Therapies
 - Phase III Trials


Background

- NAFLD is the most common cause of chronic liver disease and elevated liver enzymes.
- >80 million individuals affected in US and increasing annually
- NAFLD is one of the leading causes of cirrhosis.
- NASH is the 2nd leading cause of Liver transplant
- Most rapidly increasing indication for Liver transplant

Chalasani N HEPATOLOGY, VOL. 67, NO. 1, 2018 Younossi Z et al Clin Gastroenterol Hepatol, 2020.


Adam et al JAMA. 2020;323(12):1175-1183.

Rick Factors (High Risk) NAFLD



Chalasani N HEPATOLOGY, VOL. 67, NO. 1, 2018

NAFLD related Disease




Natural History & Disease Spectrum of NAFLD -10-45% (over 3-4 years) NAFLD 22-24% ~14 yrs to progress 1 fibrosis stage ~7% (over 3-7 years) Advanced **AFLD Activity Score** fibrosis/cirrh 10-25% osis Steatosis (0-3) (over 8-14 years) No Stage 0 5-33% 1 fibrosis 34-65% 2 **Portal** Stage I 2-130/0 (over 3-7 1 0. 16% fibrosis ≥66% 3 Ver 6 years) HCC **Peri-portal** Stage II Inflammation (0-3) fibrosis <2 under 20x 1 Bridging Stage III 2-4 under 20x 2 fibrosis >4 under 20x 3 **Cirrhosis** Stage IV Histological section Ballooning (0-2) Younossi ZM et. al. Cl -94 Goh GB Dig Dis Sci 2 Mc Pherson S J Hepatol 2015:62.1148-1155 Few 1 Pais R. J Hepatol 2013:59. 550-556 Wang VW. Gut 2010:59.969-974 Argo CK J Hepatol 2009-51:371-369 Many 2 Singh S. CGH 2015;13-643-654

Case 1- Question 1

A 60 YOF with diabetes mellitus, hypertension who comes to primary care office for regular medical check up. On examination, her BMI 33 kg/m2, the rest of the examination are negative. Her medications include Glyburide and lisinopril. Lab include AST 90 IU/L, ALT 110 IU/L, Alkaline phosphatase 210 IU/L, bilirubin 0.5, platelet 150K. Ultrasound showed bright liver. SMA 1:20, IgG 1010, AMA negative. Hepatitis A, B and C serologies were negative. What is the next investigation ?

- A. Check Fibrosure
- B. Calculate FIB 4 score
- C. CT scan abdomen
- D. MRI abdomen



Case 1 – Question 2


A 60 YOF with diabetes mellitus, hypertension who comes to primary care office for regular medical check up. On examination, her BMI 33 kg/m2, the rest of the examination are negative. Her medications include Glyburide and lisinopril. Lab include AST 90 IU/L, ALT 110 IU/L, Alkaline phosphatase 210 IU/L, platelet 150K. Ultrasound showed bright liver. SMA 1:20, IgG 1010, AMA negative. Hepatitis A, B and C serologies were negative. FIB4 score 3.43. What is the next step ?

- A. Refer to hepatology clinic
- B. CT scan abdomen
- C. MRI abdomen
- D. Liver biopsy



WHO IS THE HIGH-RISK PATIENT?

Baseline fibrosis stage, not NASH predicts mortality and time to development of severe liver disease



There was no significant difference in the number of severe liver disease cases in patients without and with NASH (9.8% vs. 12.8%, p=0.29)

Severe Liver disease- Liver failure (ICD), cirrhosis, HCC or Decompensation

HOW TO STRATIFY RISK

Which patient need to be referred to Hepatology Clinic?

STAGING OF NAFLD - FIBROSIS

- Invasive staging (Gold Standard)
- Non Invasive Tests (NIT) staging

Liver Biopsy


Invasive: Liver biopsy

Neutrophils Mallory hyaline Ballooned hepatocyte

- Gold standard
 - Clinical staging, differentiate/detect concomitant disease
 - End points of phase 3 clinical trials
- Limitations
 - Invasive
 - Small risk of complications
 - Risk of sampling error or variability
 - Low acceptance by patients
 - Inconvenience for monitoring of disease status
 - Cost

Bedossa P Hepatology 2003;38:1449-57. Siddiqui MS Hepatology 2018;67:2001-2012.


Challenges in Liver enzymes



- ALT can be normal in >50% of NASH
- ALT can be elevated in >50% of NAFLD without NASH
- Normal ALT does not preclude NASH/progressive disease
- Elevated ALT cannot predict NASH or fibrosis

Mofrad P. Hepatology 2003 Jun:37(6):1286-92 Browning. Hepatology. 2004;40:1387 Dyson. Frontline Gastroenterol.2014;5:211


Non invasive Tests (NIT) for staging



Simple NIT biomarkers

Score	Formula
FIB4	<u>Age x AST</u> (IU/I)/platelet count (x10 ⁹ /litre)x \sqrt{ALT} (IU/I).
NFS (NAFLD fibrosis score)	1.675+0.0373 <u>age</u> (years)+0.0943 <u>BMI</u> (kg/m2)+1.133impaired <u>fasting glycaemia</u> or <u>diabetes</u> (yes1⁄41, no1⁄40)+0.993 <u>AST/ALT</u> ratio 0.0133 <u>platelet</u> (31x9/litre) 0.663 <u>albumin</u> (g/dl)

Accuracy of simple NIT biomarkers (no/Mild vs advanced fibrosis)




COMPLEX TESTS

Test				D	ata			
ELF (Enhanced Liver Fibrosis panel) To assess ≥F3	DS= -7.412+(ln(HA)*0.681)+(ln(P31 (ln(TIMP1)*0.494) HA=Hyaluronic acid P3NP=Pro-collagen 3 TIMP1=Tissue Inhibitor of matrix metalloproteinase 1	SROC curve			 11 studies were included in the meta-analysis of advanced fibrosis AUC: 0.83 (0.71, 0.90) Sensitivity: 0.73 (0.60, 0.83) Specificity: 0.80 (0.68, 0.88) Sensitivity of >0.90 for excluding fibrosis at threshold of 7.7 Specificity of 0.90 for advanced and significant fibrosis ,thresholds of 10.18 (sensitivity: 0.57) and 9.86 (sensitivity: 0.55) 			
Pro-C3 based predictive fibrosis score To assess ≥F3	ABC3D = Age>50, BMI>30, C=Plat 3= Pro-C3>15.5 ng/ml, Diabetes= p (each score 1, DM score 2= max 6) FIBC3 = : -5.939 + (0.053*Age) + (0 (1.614*T2DM) – (0.009*platelets) +	je (Age>5 VI DM	ABC: 50 = 1, BMI >30 = Pro-C3 >15.5 = Score FIBC FIBC3 sco	1, Platelet count <200, 1, T2DM = 2 >3				
	C3)			FIBC3	FIB4	ABC3D		
			AUROC	0.83	0.76	0.81		
			Sensitivity	75.00	21.00	66.00		
			Specificity	75.00	94.00	75.00		

Vali et al. J.Hepatol. 2020, 73, 252–262 Boyle J Hep Reports. 2019 Jul 4;1(3):188-198 Daniels SJ. Hepatology. 2019 Mar;69(3):1075-1086

IMAGING


Liver Stiffness Measurement



Cassinotto C et al.Hepatology: 2016 Jun;63(6):1817-27, Lee H et al. Clin Gastroenterol Hepatol 2020 May 22;S1542-3565(20)30693-5 Eddowes PJ Gastroenterology. 2019 May;156(6):1717-1730 Loomba.el.al Hepatology, 2014:60-1920

ACCURACY OF MRE AND TE

POOLED ANALYSIS: 2005-2017- 3 studies with NAFLD with TE, MRE and biopsy



Hsu C.et al. Clin Gastroenterol Hepatol. 2019 Mar;17(4):630-637.e8

Discordance in Fibrosis Stage in Obese patients MRE vs TE

Discordance rate	Training Cohort (n=199)	Validation Cohort (n=75)
TE vs Biopsy	51.9%	58.8%
MRE vs Biopsy	21%	14.7%


- Discordance worsen with increased BMI
- Significantly higher for BMI >35 kg/m²

$\begin{aligned} & \text{FAST (Fibroscan-AST)} \\ & \text{Main} \\ & \text{outcome}=\text{NASH+NAS} \\ & \ge 4+F\ge 2 \end{aligned} \qquad \qquad$												
	AUROC (95% CI)	n	Prevalence of NASH + NAS ≥ 4 + F ≥ 2	Rule-out zo	one (FAST ≤0-	-35)		Grey zone (FAST 0-35-0-67), n (%)	Rule-in zon	e (FAST ≥0·6	7)	
				n (%)	Sensitivity	Specificity	NPV		n (%)	Sensitivity	Specificity	PPV
Derivation cohort	0·80 (0·76–0·85)	350	174 (50%)	113 (32%)	0-90 (157/174)	0·53 (93/176)	0-85 (93/110)	136 (39%)	101 (29%)	0-90 (159/176)	0·48 (84/174)	0-83 (84/101)
French bariatric surgery cohort	0·95 (0·91–0·99)	110	16 (15%)	69 (63%)	1·00 (16/16)	0·73 (69/94)	1·00 (69/69)	22 (20%)	19 (17%)	0-93 (87/94)	0·75 (12/16)	0·63 (12/19)
USA screening cohort	0·86 (0·80–0·93)	242	28 (12%)	194 (80%)	0-64 (18/28)	0-86 (183/214)	0·95 (183/193)	39 (16%)	9 (4%)	0-99 (212/214)	0-25 (7/28)	0.78 (7/9)
China Hong-Kong NAFLD cohort	0·85 (0·76–0·93)	83	36 (43%)	28 (34%)	0-94 (34/36)	0·55 (26/47)	0·93 (26/28)	29 (35%)	26 (31%)	0-89 (42/47)	0-58 (21/36)	0-81 (21/26)
China Wenzhou NAFLD cohort	0·84 (0·73–0·95)	104	9 (9%)	55 (53%)	0-89 (8/9)	0-56 (53/95)	0-98 (58/67)	37 (36%)	12 (11%)	0-92 (87/95)	0-44 (4/9)	0-33 (4/12)
French NAFLD cohort	0·80 (0·73–0·86)	182	78 (43%)	67 (37%)	0-88 (69/78)	0·56 (58/104)	0-87 (58/67)	69 (38%)	46 (24%)	0-89 (93/104)	0·45 (35/78)	0-76 (35/46)
Malaysian NAFLD cohort	0·85 (0·78–0·91)	176	36 (20%)	78 (44%)	0-94 (34/36)	0·54 (75/140)	0-97 (75/77)	59 (34%)	39 (22%)	0·87 (122/140)	0-58 (21/36)	0-54 (21/39)
Turkish NAFLD cohort	0·74 (0·65–0·82)	129	74 (57%)	26 (20%)	0-91 (67/74)	0·35 (19/55)	0.73 (19/26)	57 (44%)	46 (36%)	0-82 (45/55)	0-49 (36/74)	0·78 (36/46)
Pooled external patients cohort	0-85 (0-83-0-87)	1026	277 (27%)	517 (51%)	0-89 (246/277)	0·64 (483/749)	0·94 (483/514)	312 (30%)	197 (19%)	0-92 (688/749)	0-49 (136/277)	0-69 (136/197)

Newsome et.atl Lancet Gastroenterol Hepatol. 2020 Feb 3

Epub ahead of print

Narrow Indeterminate Zone



Sequential NITs to Reduce Indeterminate

Zone

Single tests

TABLE 6. Performance of Sequential Algorithms Using Two NITs to Discriminate Advanced Fibrosis (F3-F4 vs. F0-F2)

(n = 3,180)


 $\mathsf{FIB-4} (1.3, 2.67) \rightarrow \mathsf{FIB-4} (1.3, 2.67) \rightarrow$

ELF (9.8, 11.3) LS by VCTE (9.9, 11.4)

(n = 3,141)

- (either NFS, FIB4,ELF, VTE)
- Up to 50% indeterminate Variable


Prevalence of F3-F4	71%	71%
Sensitivity*	69 (67, 71)	77 (75, 78)
Specificity*	92 (90, 94)	89 (87, 91)
PPV*	96 (94, 97)	95 (93, 96)
NPV*	55 (53, 58)	60 (58, 63)
Indeterminate*	24 (23, 26)	20 (18, 21)
Misclassified*	24 (23, 26)	20 (18, 21)



Guideline for Primary Care & Diabetology

- 1. AST/ALT elevation (1.5 x ULN $x \ge 6$ months)
- 2. History of fatty liver (US, CT, MRI or Liver biopsy)
- 3. T2DM with 1 additional component of metabolic syndrome
- 4. Non-diabetes with 3 components of metabolic syndrome

- For those with elevated AST/ALT x 6 months- other cause of liver disease should be excluded
- For those without previous imaging, US should be performed



Younossi Z et al Aliment Pharmacol Ther. 2020;52(3):513-526.

Case 1-Answer 1

A 60 YOF with diabetes mellitus, hypertension who comes to primary care office for regular medical check up. On examination, her BMI 33 kg/m2, the rest of the examination are negative. Her medications include Glyburide and lisinopril. Lab include AST 90 IU/L, ALT 110 IU/L, Alkaline phosphatase 210 IU/L, bilirubin 0.5, platelet 150K. Ultrasound showed bright liver. SMA 1:20, IgG 1010, AMA negative. Hepatitis A, B and C serologies were negative.

What is the next investigation ?

- A. Check Fibrosure
- B. Calculate FIB 4 score
- C. CT scan abdomen
- D. MRI abdomen

- Risk stratification is important
- FIB4 3.43 which is >1.3



Case 1 – Answer 2

A 60 YOF with diabetes mellitus, hypertension who comes to primary care office for regular medical check up. On examination, her BMI 33 kg/m2, the rest of the examination are negative. Her medications include Glyburide and lisinopril. Lab include AST 90 IU/L, ALT 110 IU/L, Alkaline phosphatase 210 IU/L, platelet 150K. Ultrasound showed bright liver. SMA 1:20, IgG 1010, AMA negative. Hepatitis A, B and C serologies were negative.

What is the next step?

- A. Refer to hepatology clinic
- B. CT scan abdomen
- C. MRI abdomen
- D. Liver biopsy

FIB4 3.43 which is >1.3 \rightarrow refer to Hepatology clinic




MANAGEMENT


Case 3 - Question

A 60 YOF with diabetes mellitus, hypertension who comes to primary care office for regular medical check up. She denied drinking alcohol. On examination, her BMI 31 kg/m2, the rest of the examination are negative. Lab include AST 90 IU/L, ALT 110 IU/L, Alkaline phosphatase 210 IU/L, platelet 150K. Ultrasound showed bright liver. SMA 1:20, IgG 1010, AMA negative. Ferritin 600, % saturation iron 25%, Hepatitis A, B and C serologies were negative.

What is the most beneficial therapy?

- A. Phlebotomy
- B. Weight loss
- C. Pioglitazone
- D. Prednisone





Romero-Gómez M, et al. J Hepatol. 2017Oct;67(4):829-846 Vilar-Gomez E et al. Gastroenterology.2015 Aug;149(2):367-78.35


Dietary Changes

MEDITERRANEAN DIET TYPICAL PLATE

-

									Vegetables and	of red wine	I
	Daily Ca	• 1200-1600 calories					Crains/rice/pasta 25%	fruits sols ()	1 - 2 servings of olive oil	ê	
	Lipio	 20-30% of daily calories Rich in MUFA and PUFA									
	Prote	1.5 g/kg/dayRich in plant-based protein									
	Carbohy	drates	 <45-65% of daily calories with decreased simple sugar 								
Low CHO diet Mediterra		anean diet		Coffee (caffeinated, filtered)			Alcc consur		on		
 Improves liver fat metabolism Improve steatosis even wit weight le Reduce events, syndrom 		s, IR, thout oss CV metabolic		 ≥3 cups/day- decrease mortality Reduce fibrosis 		a • L fc d • L fe	Reduce bstinen imit ≤2 or fema rinks/d imit 20g emale, s nale	ice drinł le, ≤ for n g/d fo	3 nale or		

Vlad Ratziu 1, et al. Transplantation. 2019 Jan;103(1):28-38. Romero-Gómez M, et al. J Hepatol. 2017Oct;67(4):829-846.Torres M et al. <u>Nutrients</u>. 2019 Dec; 11(12): 2971.




THERAPIES FOR NAFLD/NASH

Medical and Surgical/Endoscopic Therapies

PIVENS Study

• RCT phase 3 trial -247 biopsy proven NASH without DM or cirrhosis



AASLD Guideline

Pioglitazone

 with and without T2DM with biopsy-proven NASH

Vitamin E

- Non DM adults with biopsy-proven NASH
- Not in DM, non biopsy, NASH cirrhosis or cryptogenic cirrhosis
 - May be considered to treat biopsy proven NASH in diabetic patients
 - Need more data on safety & long term mortality

Weight Loss Therapies

Pharmacotherapy

- GLP-1 RA (Liraglutide)
- Others- orlistat, Phentermine, Natrexone/Bupropion

Mean 8-13% total body wt loss


Endoscopic Bariatric

- Gastric Balloon
- Sleeve Gastroplasty
- DMR (duodenal mucosal resurfacing)
- Gastric emptying
- Duodenal-jejunal bypass sleeves

Bariatric Surgery


- Rou-en-Y Gastric bypass
- Sleeve Gastroplasty

Intragastric Gastric Balloon Placement induces Significant Metabolic & Histologic Improvement in patients with NASH



Bariatric Surgery Provides Long-Term Resolution of NASH and





NASH was resolved, without worsening fibrosis, in samples from 84% of patients (n = 64; 95% confidence interval,73.1%-92.2%)

main surgical procedure was gastric bypass (66.1%)

In a subgroup analysis comparing gastric banding to gastric bypass, gastric bypass was significantly more effective in achieving the primary endpoint p=.03.

Bariatric Surgery Reduces Cancer Risk in Adults with NAFLD & Severe Obesity

Table 3. Hazard Ratios of Obesity-Related Cancer in Patients With Versus Without Bariatric Surgery,^a Adults With Nonalcoholic Fatty Liver Disease and Severe Obesity, 2008-2017 (N = 98,090)

Retrospective cohort study of 18 - 64 years old newly diagnosed NAFLD patients with severe obesity between 2007 and 2017 Total of 98.090 patients were included → 33,435 (34.1%)

received bariatric

surgery

Type of obesity-related cancer	Events, No.	Unadjusted	Adjusted ^b		
Any obesity-related cancer	911	0.62 (0.54-0.72)	0.65 (0.56-0.75)		
Colon cancer	116	0.64 (0.41-0.96)	0.66 (0.42-1.00)		
Rectal cancer	15	0.41 (0.09-1.31)	0.44 (0.10-1.37)		
Postmenopausal breast cancer	131	0.75 (0.51-1.08)	1.08 (0.74–1.54)		
Hepatocellular carcinoma	49	0.32 (0.15-0.65)	0.48 (0.24-0.89)		
Kidney cancer	120	0.81 (0.54-1.18)	0.90 (0.60-1.32)		
Esophageal cancer	16	0.31 (0.07-1.01)	0.33 (0.06-1.18)		
Cancer of the gastric cardia	8	0.30 (0.02-1.70)	0.46 (0.03-2.44)		
Gallbladder cancer	4	1.04 (0.11-9.33)	0.99 (0.05-12.58)		
Pancreatic cancer	44	0.35 (0.15-0.73)	0.46 (0.21-0.93)		
Ovarian cancer	74	0.70 (0.42-1.14)	0.70 (0.41-1.15)		
Endometrial cancer	135	0.45 (0.30-0.66)	0.49 (0.31-0.73)		
Thyroid cancer	143	0.69 (0.47-0.98)	0.61 (0.41-0.89)		
Multiple myeloma	50	0.40 (0.19–0.77)	0.33 (0.14-0.69)		
Meningioma	6	0.66 (0.09-3.45)	0.52 (0.05-2.90)		

^aBariatric surgery status included as a time-dependent covariate.

^bUsing IPTW adjusted for age, health insurance type, region of residence, year of NAFLD diagnosis, sex, smoking, asthma obstructive sleep apnea, obesity hypoventilation syndrome, osteoarthritis, diabetes, hypertension, cardiovascular disease, disease.

Bariatric surgery significantly decreases the risk of any cancer and obesity-related cancer in individuals who copresent with severe obesity and NAFLD, especially those with NAFLD- cirrhosis.			sent cancer		Obesity-related cancer ^b			
			_D- HR (9	5% CI)		HR (95% CI)		
	Variable	Participants, No.	Events, No.	Unadjusted	Adjusted ^c	Events, No.	Unadjusted	Adjusted ^c
	Cirrhosis ^{d,e}							
	No	95,235	2695	0.77 (0.71-0.84)	0.83 (0.76-0.90)	859	0.64 (0.55-0.74)	0.67 (0.57-0.78)
	Yes	2855	128	0.50 (0.33-0.73)	0.52 (0.34-0.77)	52	0.39 (0.19-0.71)	0.32 (0.15-0.64)


HR (95% CI)

PATIENTS WITH T2DM


- GLP-1 agonist –proven CV benefit
- SGLT 2 inhibitor proven HF and CKD benefit

Glucagon-Like Peptide-1 (GLP-1) Agonists (Liraglutide) LEAN TRIAL

- Phase 2: LEAN Trial: RCT 52 pts (Histo proven NASH) – 1.8 mg/d Liraglutide SC or Placebo for 48 weeks.
- Primary Endpoint: resolution of NASH with no worsening of fibrosis at the end of the study
- 39% vs 9% relative risk 4.3
 [95% Cl 1,0–17,7]; P .019



Glucagon-Like Peptide-1 (GLP-1) Agonists (Liraglutide)



Armstrong MJ et al. Lancet 2016;387(10019):679–90.

Marso et al, N Engl J Med. 2016 Jul 28;375(4):311-22


Type 2 DM

Semaglutide (GLP1 Agonist)

Phase 2 RCT in 320 patients NASH (F2-F3 fibrosis) at Wk 72

Semaglutide 0.1 mg Semaglutide 0.2mg

Semaglutide 0.4 mg Placebo




NASH resolution without worsening of fibrosis

- Less fibrosis progression
- Dose dependent improved in AST, ALT,GGT
- Weight loss up to 12.5% vs 0.6% placebo
- Reduced HbA1C

Newsome P et al. N Engl J Med. 2021 Mar 25;384(12):1113-1124

Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor-Empagliflozin in NAFLD with type 2 DM

Patients with T2D (n=84) (HbA₁₀ $6.6\pm0.5\%$ [49610 mmol/mol], known disease duration 39 ± 27 months) were randomly assigned to 24 weeks of treatment with 25 mg PO daily EMPA or placebo



LFC (liver fat content)- measured by volumeselective proton MRS (1H-MRS) N = 42 EMPA vs N= 42 Placebo

At 24 weeks, a placebo-corrected absolute (21.8% [23.4, 20.2]; P 5 0.02) and relative decrease in LFC (222%; P 5 0.009) was observed

Kahl et al. Diabetes Care 2020;43:298-305

Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor-Empagliflozin in NAFD without type 2 DM

Double-blind, placebo-controlled clinical trial, participants with NAFLD were randomized to empagliflozin (10 mg/day) (n = 43) or placebo (n = 47) for 24 weeks

Hepatic steatosis and fibrosis were assessed using transient elastography to measure the controlled attenuation parameter (CAP) and liver stiffness measurement (LSM).

primary outcome →the change in CAP score at 24 weeks

	Empagliflozin (n [§])		Placebo (n^{δ})			P value	
	Enrollment	EOT	P value	Enrollment	EOT	P value	
CAP score	306.5 (24.0)	277.7 (31.9)	0.001	304.6 (27.2)	281.2 (34.7)	0.001	0.396
S1 > 302 dB/m (%)	41.9	16.3	0.010	29.8	23.4	0.001	0.035
S2 > 331 dB/m (%)	0	0		2.1	0		
S3 > 337 dB/m (%)	11.6	0		12.8	4.3		
$S \ge S1$	53.5	16.3		44.7	27.7		
LSM, kPa	6.03 (1.40)	5.33 (1.08)	0.001	5.56 (1.05)	5.35 (0.96)	0.139	0.039

 Moderate intensity physical activity

3–6 times the metabolic equivalent task (METs) for at least 45 min without interruption x > 3times/week


Standard dietary advice as well

Taheri H et al. Adv Ther (2020) 37:4697-4708

PHASE III CLINICAL TRIALS

- Obeticholic acid FXR agonist
- Lanifibranor PPAR agonists
- Resmetirom THR-beta Agonists
- Aramchol –a partial inhibitor of hepatic stearoyl-CoA desaturase (SCD1)/SCD-1 Modulator
- Semaglutide GLP=1 (injectable)

Combination Therapy for NASH-Rationale, Opportunities and Challenges




Dufour J-F, et al. Gut 2020;0:1-8. doi:10.1136 gutjnl-2019-319104


Case 3 - Answer

A 60 YOF with diabetes mellitus, hypertension who comes to primary care office for regular medical check up. She denied drinking alcohol. On examination, her BMI 33 kg/m2, the rest of the examination are negative. Lab include AST 90 IU/L, ALT 110 IU/L, Alkaline phosphatase 210 IU/L, platelet 150K. Ultrasound showed bright liver. SMA 1:20, IgG 1010, AMA negative. Ferritin 600, % saturation iron 25%, Hepatitis A, B and C serologies were negative.

What is the most beneficial therapy ?

- A. Phlebotomy
- B. Pioglitazone
- C. Weight loss
- D. Prednisone





Thank you!